Safety and Efficacy of Ranibizumab in Macular Edema following Retinal Vein Occlusion | Zendy

Roberto GallegoPinazo | Zendy; Rosa DolzMarco | Zendy; C. Marín-Lambíes | Zendy; M. Díaz-Llopis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Safety and Efficacy of Ranibizumab in Macular Edema following Retinal Vein Occlusion

Author(s) -

Roberto GallegoPinazo,

Rosa DolzMarco,

C. Marín-Lambíes,

M. Díaz-Llopis

Publication year - 2012

Publication title -

ophthalmology and eye diseases

Language(s) - English

Resource type - Journals

ISSN - 1179-1721

DOI - 10.4137/oed.s7264

Subject(s) - medicine , ranibizumab , macular edema , ophthalmology , retinal vein , branch retinal vein occlusion , retinal , clinical trial , central retinal vein occlusion , occlusion , surgery , bevacizumab , chemotherapy

Macular edema is the leading cause of visual impairment in patients with retinal vein occlusion. Limited improvements may be obtained with laser photocoagulation or intravitreal triamcinolone. However, according to the data provided by randomized clinical trials, intravitreal injections of ranibizumab (Lucentis; Genentech, South San Francisco, CA) constitute a new effective and safe option for the management of these vision-threatening diseases. The aim of the present review is to summarize the clinical evidence of ranibizumab for macular edema due to retinal vein occlusions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research